News / Taiwan / economic_daily
Tensei Biomedical to List on Taipei Exchange in December, Targeting Human and Pet Health Markets
Consumer Non-Durables · Household/Personal Care · economic_daily · 2026-11-02
7889
Tensei Biomedical is set to debut on the Taipei Exchange this December, leveraging its dual-brand strategy in human and pet supplements to drive growth.
What Happened
IPO Plans: Tensei Biomedical is scheduled to officially list on the Taipei Exchange this December. The company has demonstrated strong operational resilience and profitability through its multi-brand matrix strategy in the health and wellness sector.
Brand Portfolio: The company operates two flagship brands, 'Damo' for traditional herbal supplements and 'Pet's Age' for pet health products, catering to the comprehensive needs of modern households. In the first half of this year, human and pet product sales accounted for 68% and 31% of total revenue, respectively.
Omnichannel Strategy: Starting as an e-commerce player, Tensei has successfully expanded into over 6,900 physical retail locations, including major pharmacy chains, convenience stores, and pet specialty shops. The increasing contribution from physical channels has become a key driver of the company's recent growth.
Future Outlook: Management maintains a cautiously optimistic outlook, focusing on expanding its brand matrix and pursuing cross-industry B2B partnerships. By leveraging its robust omnichannel presence, the company aims to capitalize on the global growth of the health and wellness industry.